Home
This site is intended for healthcare professionals

Global OSA Institute Insights Podcast: Episode 1 – Spotting OSA Earlier

Share

Description

This program is supported by an independent educational grant from Lilly.

Join Dr. Douglas Kirsch for this CME-accredited podcast as he explores how clinicians can recognize when cardiometabolic risk should trigger targeted case-finding for obstructive sleep apnea (OSA) and integrate OSA assessment into routine cardiometabolic care.

Through a real-world patient case, this episode examines practical approaches to identifying patients at high risk of OSA, selecting appropriate screening and diagnostic strategies, and coordinating follow-up to support both OSA management and cardiometabolic health.

This is episode one of three, find episodes two and three here.

Who Should Listen?

Primary care physicians and sleep specialists involved in the care of patients with OSA.

This podcast has four segments:

  • Recognizing OSA Risk – Uncover the cardiometabolic clues that may point to undiagnosed OSA.
  • Identifying Patients for Assessment – Learn how targeted case-finding can help bring high-risk patients into focus.
  • Choosing the Diagnostic Approach – Explore practical strategies for moving from OSA suspicion to the right diagnostic test.
  • Coordinating OSA Care and Follow-Up – Discover how to connect OSA management with ongoing cardiometabolic care for more coordinated follow-up.

Faculty

Dr Douglas Kirsch is Medical Director of Sleep Medicine at Atrium Health and a Professor of Internal Medicine and Neurology. A board-certified sleep medicine specialist, he has extensive expertise in the diagnosis and management of sleep disorders, with a particular research focus on obstructive sleep apnea. His research examines the impact of OSA treatment on patient hospitalizations and explores the use of consumer wearable devices to assess sleep in the home setting. Dr Kirsch is a former President of the American Academy of Sleep Medicine and is dedicated to improving sleep health and patient well-being.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Douglas Kirsch, faculty for this educational activity, has the following relevant financial relationships: Scientific Advisory Board Apnimed, Incannex, Huxley Medical. Expert Panel Carelon. Consulting ResMed.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Associate Continuing Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information

There is no fee for this educational activity.

This continuing education activity is active starting October 6th 2026, and will expire on July 1st 2028.

Learning objectives

By the end of this Program Learners should be better able to:

Integrate OSA diagnosis into cardiometabolic risk assessment and management through screening of high-risk patients and coordinated cardiometabolic care.

Implement evidence-based, multimodal OSA treatment plans that integrate PAP therapy, cardiometabolic management, and emerging pharmacotherapy, applying a multidisciplinary, chronic-disease model.

Implement simplified, accessible diagnostic algorithms and integrated obesity-CVD-OSA care pathways to overcome diagnostic bottlenecks, reduce care fragmentation, and improve timely access to evidence-based treatment for patients with moderate-to-severe OSA across diverse healthcare settings.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

Hello and welcome to Global OSA Institute Insights. This episode is titled Spotting OSA Earlier. This independent accredited educational activity is intended for primary care physicians and sleep specialists who care for adults with obstructive sleep apnea. It is supported by an independent educational grant from Lilly. Today we are joined by Doctor Douglas Kirsch, medical director of sleep medicine for Atrium Health and professor at the Wake Forest School of Medicine. Today we will focus on how OSA casefinding can be embedded into routine cardio metabolic care in the United States. Let's start with the first case. A 56-year-old woman has obesity, resistant hypertension, type 2 diabetes, and dyslipidemia. BMI is 36 kg per square meter. BP is 158.94. Of a millimeter of mercury, despite an ARB, a calcium channel blocker, and a thiazide-like diuretic. HbA1c is 7.8%, 62 millimoles per mole. LDL cholesterol is 3.1 millimoles per liter, 120 mg per deciliter, and EGFR is 78 mL per minute per 1.73 square meters. She reports fatigue, morning headaches, and nocturia. Her partner reports loud snoring. Her cardio metabolic medication has been intensified, but no sleep history. Validated OSA risk assessment or diagnostic pathway is documented. Decision point. What should the clinician recognize and do now, rather than waiting for more obvious sleepiness or a future cardiovascular event? Let's turn to Doctor Kirsch. Doctor Kirsch, when you look at this case, where exactly is the missed clinical decision? And why should obstructive sleep apnea be considered part of the cardio metabolic assessment, rather than a separate sleep complaint? Well, I think it's important to start with the fact that people don't always think about sleep when they think about these patients who are complex. Um, but it can be an important part of assessing this patient and helping them through all these medical problems that they have. And so, in this patient, we have a couple of signals that are relevant. Uh, you have obesity, resistant hypertension, diabetes. And those in combination could be related to sleep apnea, particularly obstructive sleep apnea. And so I think that that's, that's the first thing is in your head saying, hey, in this patient, is there something that may link all these pieces together. Once you make that decision to say, hey, is sleep a problem? It's worth asking some questions. Now, in this particular case, we found out that they're fatigued, there's some loud snoring, there's some trips to the bathroom at nighttime, some morning headaches. These are all triggers that should definitely make you think about sleep apnea. You should not miss that at that point. Oh, apologies. You should not miss that at that point. And so now it's a question of, do you want to screen them for sleep apnea by asking and using a standardized questionnaire, or do you want to move straight ahead and do some form of sleep testing or refer to a sleep practice to do that testing? Which patients should trigger OSA case finding during routine cardio metabolic care, even if they do not spontaneously complain of daytime sleepiness? So, I think the first thing to think about when you're talking about patients who have cardio metabolic conditions are what kinds of things are you thinking about here? Are these patients who are obese, do they have difficult to control hypertension? Are they, do they have atrial fibrillation or heart failure or coronary artery disease? Any of these are things in your head that should make you think a little bit about sleep apnea to start with. It's important to recognize that daytime sleepiness is not the only symptom that someone with obstructive sleep apnea might have, and in fact, some number of people don't ever complain of daytime sleepiness. And so recognizing that just because somebody doesn't tell you this, It doesn't mean A that they don't have it, so some people will not talk about it unless asked, and B, some people will not complain about it as a symptom, though other people might notice it for them. So for instance, a partner may say, you're always falling asleep in conversations or falling asleep when guests are over, but the patient may not always view that as a problem. So, in this particular case, it's worth thinking about screening this patient more structurally for sleep apnea and how might you do that. Um, classically, a stop bang questionnaire is something you might choose to do. This is an 8 question survey, um, that asks about a series of questions, trying to get at the point of, does this patient have a higher risk for obstructive sleep apnea. Alternatively to a structured questionnaire, you could ask some questions like, do you snore? Do you stop breathing at nighttime, or has anybody ever said that to you? Do you gasp or choke during the night? Do you wake up a lot during the night, or do you have morning headaches? These are some of the common things that you might uh ask about. As a side note, I in my clinic will always ask about whether somebody is drowsy driving. This is an urgent safety concern, um, and you will be surprised when you ask that question, how many people, at least in a sleep clinic, might say yes to it. So In summary, what should we be thinking about here? In somebody who has obesity and either has some form of cardio metabolic condition or might be resistant hypertension, you might begin to think about screening for sleep apnea and or asking some targeted questions about sleep apnea. For a busy clinic, what should a high quality 62nd OSA risk assessment contain? And how should validated questionnaires and the Epworth sleepiness scale be used without confusing screening with diagnosis? So this is a good question. I think it's important to start with the fact that you can ask about obstructive sleep apnea very quickly in patients. Asking very simple questions such as, do you snore or stop breathing at nighttime, and are you sleepy during the daytime will already give you a reasonable sense of maybe where there might be a problem. However, Validated tools can be helpful here, such as a stop bang, which I mentioned previously, an 8 question survey, the Berlin questionnaire, or other questionnaires can be helpful in assessment of sleep apnea. The Epworth Sleepiness Scale, uh, which was mentioned, is a tool that assesses how sleepy someone is. But it does not diagnose sleep apnea. Some number of people with sleep apnea will score quite low on an Epworth sleepiness scale, and some people who score quite high on Epworth sleepiness scale won't have sleep apnea. So it's good to assess sleepiness as a broad category, but it may or may not exclude sleep apnea as a diagnosis. So, recognize that even when tools are maybe not pointing you in the right direction, but you have a high clinical suspicion based on the story, it's worth investigating further. Um. Always make sure, again, if somebody is doing a job in which they, sleepiness is a safety concern. So if they're working on ladders, if they are driving uh a fair amount, always make sure you're asking about sleepiness to some level to make sure that they are safe, cause that is our job as clinicians to make sure our patients are uh safe in what they do. But then also making sure that just if they are or aren't sleepy, it doesn't necessarily mean that they don't have sleep apnea. That using a questionnaire, using tools, uh, or targeted questions can help you think through the question of, do I need to take this a step further, um, from, hey, this is a higher-risk patient for sleep apnea to the next step of testing or referral to a sleep clinic. Now a question for our listeners. Think of the last patient you saw with obesity and difficult to control hypertension. Was OSA risk documented and what specific finding would have triggered testing in your system? OK, now back to Doctor Kirsch. Suppose this patient has a high risk questionnaire result. What should happen next? And how do you decide between home sleep apnea testing and in laboratory polysomnography? So there are a couple ways that we think about trying to decide what test is appropriate for a patient. Um The first, uh, is, is the test appropriate for a patient based on medical assessment. So, home testing is really good in uncomplicated patients, um, who are at moderate to high risk for obstructive sleep apnea. Um, this is a test that is done in the patient's home. It is relatively easy for most patients to complete. And it's relatively less expensive than uh in laboratory testing. It is often preferred by insurance companies for that.